NATCO Pharma said that it has received approval of its ANDA for Everolimus tablets for oral suspension (TFOS), a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

Billings reached 50° for the first time in January 2025. We might be able to do that again on Thursday and Saturday, but there are changes beyond that.

Raymond James analyst S. Hansen now anticipates that the company will post earnings per share of $4.21 for […] ...

In total, 205 rail construction projects broke ground in 2024, with a combined capital investment of almost $390bn ...

Bioxyne lifts revenue 77% QoQ; Radiopharm listed on the Nasdaq in the December quarter; Tryptomine hits key milestones; Quarterly season is nearing its end, triggering a rush from ...

Microsoft shared details on the company's financial results for Q2 FY25 on Wednesday, revealing that gaming revenue was down ...

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where ...

President Trump on Monday fired all three Democrats on the Privacy and Civil Liberties Oversight Board (PCLOB), bringing much ...

In terms of Xbox, Microsoft mentions that a "business highlight" is the 2% increase in content and services revenue, said to ...

Microsoft pulls in over $6.58 billion in revenue from its Xbox games division throughout Holiday 2024, driven primarily by ...

Microsoft said that its capital expenditures soared in its fiscal second quarter $22.6 billion, up 96% from $11.5 billion a year ago, to support the demand in its cloud and AI offerings. In its slides ...

Class III futures were reluctant to follow several days of green with further higher price action, and showed modest declines ...